GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Abiomed Inc (NAS:ABMD) » Definitions » Net Current Asset Value

Abiomed (Abiomed) Net Current Asset Value : $20.06 (As of Sep. 2022)


View and export this data going back to 1987. Start your Free Trial

What is Abiomed Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Abiomed's net current asset value per share for the quarter that ended in Sep. 2022 was $20.06.

The historical rank and industry rank for Abiomed's Net Current Asset Value or its related term are showing as below:

ABMD' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.08   Med: 8.43   Max: 44.9
Current: 18.99

During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Abiomed was 44.90. The lowest was 1.08. And the median was 8.43.

ABMD's Price-to-Net-Current-Asset-Value is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 5.04 vs ABMD: 18.99

Abiomed Net Current Asset Value Historical Data

The historical data trend for Abiomed's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abiomed Net Current Asset Value Chart

Abiomed Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
Net Current Asset Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.96 12.40 10.77 13.77 17.71

Abiomed Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.96 15.93 17.71 19.60 20.06

Competitive Comparison of Abiomed's Net Current Asset Value

For the Medical Devices subindustry, Abiomed's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abiomed's Price-to-Net-Current-Asset-Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Abiomed's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Abiomed's Price-to-Net-Current-Asset-Value falls into.



Abiomed Net Current Asset Value Calculation

Abiomed's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Mar. 2022 is calculated as

Net Current Asset Value Per Share(A: Mar. 2022 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(976.473-170.067-0-0)/45.545
=17.71

Abiomed's Net Current Asset Value (NCAV) per share for the quarter that ended in Sep. 2022 is calculated as

Net Current Asset Value Per Share(Q: Sep. 2022 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(1062.798-156.757-0-0)/45.172
=20.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Abiomed  (NAS:ABMD) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Abiomed Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Abiomed's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Abiomed (Abiomed) Business Description

Traded in Other Exchanges
N/A
Address
22 Cherry Hill Drive, Danvers, MA, USA, 01923
Abiomed Inc provides temporary mechanical circulatory support devices that are primarily used by interventional cardiologists and heart surgeons. The firm's products are used for patients in need of hemodynamic support before, during, or after angioplasty and heart surgery procedures. Abiomed receives the majority of revenue from its Impella product portfolio, which includes percutaneous micro heart pumps with integration motors and sensors and percutaneous catheter-based axial flow pumps. Abiomed generates the majority of its revenue in the United States.
Executives
Matthew T. Plano officer: VP, GLOBAL OPERATIONS C/O ABIOMED, INC., 22 CHERRY HILL DRIVE, DANVERS MA 01923
Martin P Sutter director 2170 BUCKTHORNE PLACE, SUITE 170, THE WOODLAND TX 77380
David M Weber officer: Chief Operating Officer 2341 ROMANO CIRCLE, PLEASANTON CA 94566
Todd A Trapp officer: Vice President, CFO C/O WATTS WATER TECHNOLOGIES, INC., 815 CHESTNUT STREET, NORTH ANDOVER MA 01845
Michael R Minogue director, officer: President & CEO 22 CHERRY HILL DR, C/O ABIOMED INC, DANVERS MA 01923
Paul Thomas director ONE MILLENNIUM WAY, BRANCHBURG NJ 08876
Paula A Johnson director 22 CHERRY HILL DRIVE, DANVERS MA 01923
Myron L Rolle director 1 NASHUA STREET, APARTMENT 1701, BOSTON MA 02114-1625
Dorothy E Puhy director DANA FARBER CANCER INSTITUTE, 44 BINNEY STREET, RM. D1632, BOSTON MA 02115
Andrew J Greenfield officer: VP Healthcare Solutions 14 HILLSIDE DRIVE, GEORGETOWN MA 01833
Marc A Began officer: VP & General Counsel C/O ABIOMED, INC., 22 CHERRY HILL DRIVE, DANVERS MA 01923
Michael G Howley officer: Vice President 22 CHERRY HILL DRIVE, DANVERS MA 01923
William J Bolt officer: SVP, DA and QA C/O ABIOMED INC, 22 CHERRY HILL DRIVE, DANVERS MA 01923
Rose Eric A Md director 161 FORT WASHINGTON AVENUE, 7TH FLOOR, NEW YORK NY 10032
Henri A Termeer director ONE KENDALL SQUARE, CAMBRIDGE MA 02139